Last reviewed · How we verify
NCT06211725: VANGAS
The VANGAS-Trial. The Value of Neurofilament Light Chain and Glial Fibrillary Acid Protein in the Blood of Patients With Asymptomatic Carotid Artery Stenosis
trial in Carotid Artery Stenosis in 200 participants. Status unknown.
1 January 2025
Quick facts
| Lead sponsor | Heinrich-Heine University, Duesseldorf |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 January 2023 |
| Primary completion | 1 January 2025 |
| Estimated completion | 1 January 2025 |
| Sites | 2 locations across Germany |
Conditions studied
- Carotid Artery Stenosis — all drugs for Carotid Artery Stenosis →
- Carotid Artery Stenosis Asymptomatic — all drugs for Carotid Artery Stenosis Asymptomatic →
- Carotid Artery Diseases — all drugs for Carotid Artery Diseases →
- Carotid Artery Plaque — all drugs for Carotid Artery Plaque →
Sponsor
Heinrich-Heine University, Duesseldorf
Who can join
Adults 60 to 80, any sex, with Carotid Artery Stenosis or Carotid Artery Stenosis Asymptomatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Stroke is the second leading cause of death and the third leading cause of disability worldwide. The cause is usually either a blockage or a severe narrowing of a cerebral artery. An important part of stroke prevention is the diagnosis and clarification of stenosis in the arteries supplying the brain, both inside and outside the skull, in order to diagnose a high-grade stenosis at an early stage and offer the patient revascularization. In particular, asymptomatic carotid artery stenosis confronts the diagnosing physician with the question of whether revascularisation is necessary. Risk factors for stroke in asymptomatic carotid artery stenosis include contralateral TIA or cerebral infarction, male gender, rapid progression of the degree of stenosis, plaque morphology, clinically silent cerebral infarctions, Doppler sonographic evidence of microemboli or reduced vasomotor reserve. An established biomarker does not exist at this time. A candidate for such a biomarker in the blood is the protein \"neurofilament light chain\" (NFL), which is already established in the diagnosis of dementia. As a component of the cytoskeleton of neurons, it is released into the patient\'s blood when the cells are damaged and can be measured there. Another candidate is glial fibrillary acid protein (GFAP), a part of the cytoskeleton of glial cells that is also released into the blood when glial cells are damaged. A systematic investigation of the value of neurofilament light chain and the glial fibrillary acidic protein in the blood of patients with asymptomatic carotid stenosis is still lacking. VANGAS determines the value of NFL and GFAP from the blood of patients with asymptomatic carotid stenosis to determine associations with the degree of stenosis, the natural course of the stenosis (increase or decrease) and possible symptoms of the stenosis as well as the functional outcome after symptomatic stenosis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Serum levels of neurofilament light chain (NfL) and glial fibrillary acid protein (GFAP) in patients with asymptomatic and symptomatic carotid artery stenosis.
Jansen R, Wagenhäuser MU, Kölsche T, Papasimos C, et al · · 2026 · cited 1× · PMID 41783480 · DOI 10.1016/j.jvssci.2026.100408
Verify or expand the search:
- PubMed search for NCT06211725
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Carotid Artery Stenosis
Currently open trials in the same condition.
- NCT07370246 — CAS for Stenosis With High-risk Features for CEA · NA · recruiting
- NCT07247864 — Balloon Guide Catheter Combined With Filter Protection for Carotid Artery Stenting · NA · recruiting
- NCT06924593 — Study on the Trans-Carotid Artery Occlusion Shunt System · NA · recruiting
- NCT07034157 — A Real-World Study on Ultrasound-Based Screening and Integrated Therapeutic Strategies for Patients With Concomitant Cor · recruiting
- NCT06936176 — Prospective Trial of IVL for Calcified Carotid Lesions(CREATE Trial) · NA · recruiting
Other Heinrich-Heine University, Duesseldorf trials
Trials by the same sponsor.
- NCT04993508 — Randomized Prospective Multi Center Cohort Study for Primary Diagnosis of Clinically Significant Prostate Cancer With Co · NA · not yet recruiting
- NCT07385482 — Chronic and Acute Cardiovascular Diseases in Elderly Intensive Care Patients · not yet recruiting
- NCT07455097 — COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P) · active not recruiting
- NCT07254663 — GEL & MEDication Dysphagia · recruiting
- NCT06313944 — German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06211725 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Heinrich-Heine University, Duesseldorf
- Last refreshed: 18 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06211725.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing